Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients—Room for Improvement and Much to Learn

Hill, Joshua A.

doi:10.1001/jamanetworkopen.2021.27454

Cited by 8 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 76% of patients obtained sufficient immunogenicity. Recent studies have reported that seroconversion after two doses of vaccination reaches 75-86% in allogeneic HSCT patients [7,12,[15][16][17][18]; our present results are consistent with this level. In one previous report, the main factor influencing vaccination response was the time elapsed from HSCT, with lower responses occurring within one year of HSCT [15].…”

Section: Discussionsupporting

confidence: 92%

“…However, the safety and efficacy of this vaccine for HSCT patients remain to be investigated because these patients were excluded from the initial registration trials. Some studies have reported the safety and efficacy of SARS-CoV-2 vaccines for HSCT patients [6][7][8]. Efficacy and safety need to be determined with regard to allogeneic transplantation and ethnic differences, as is also the case with GVHD [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation

et al. 2022

View full text Add to dashboard Cite

Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…At the beginning of the 21st century, with the deepening of molecular biology research, NSCLC can be classified into molecular phenotypes according to the different expressions of various molecular markers, and new drugs can be developed to carry out targeted individual molecular targeted therapy by targeting the driving genes related to tumor genesis and development [ 30 – 34 ]. At present, personalized therapy based on molecular markers has moved from the laboratory to the clinic [ 35 ]. In this study, we found that the expression of VIM-AS1 is significantly higher in NSCLC tissues than that in adjacent normal tissues, and VIM-AS1 expression is positively correlated with tumor pathological grades, TNM stages, and distant metastasis of NSCLC, as well as the clinical outcomes of NSCLC patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model

Tian

Guo

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. Bioinformatics methods were used to analyze non-small-cell lung cancer gene chip data, screen differentially expressed genes (DEGs), explore biomarkers related to NSCLC prognosis, provide new targets for the treatment of NSCLC, and build immunotyping and line-map model. Methods. NSCLC-related gene chip data were downloaded from the GEO database, and the common DEGs of the two datasets were screened by using the GEO2R tool and FunRich 3.1.3 software. DAVID database was used for GO analysis and KEGG analysis of DEGs, and protein-protein interaction (PPI) network was constructed by STRING database and Cytoscape 3.8.0 software, and the top 20 hub genes were analyzed and screened out. The expression of pivot genes and their relationship with prognosis were verified by multiple external databases. Results. 159 common DEGs were screened from the two datasets. PPI network was constructed and analyzed, and the genes with the top 20 connectivity were selected as the pivotal genes of this study. The results of survival analysis and the patients’ survival curve was reflected in the line graph model of NSCLC. Conclusion. Through the screening and identification of the VIM-AS1 gene, as well as the analysis of immune infiltration and immune typing, the successful establishment of the rosette model has a certain guiding value for the molecular targeted therapy of patients with non-small-cell lung cancer.

show abstract

“…but that approximately 25% of patients did not achieve seroconversion. Several reports revealed that some immunocompromised hosts, such as patients taking immunosuppressive agents or with hematological disease, had difficulty obtaining immunogenicity and that antibody titers against the S1 spike protein decreased early [4,5]. A recent systematic review and meta-analysis has shown that immune response to COVID-19 vaccines is impaired in HSCT patients, with a seropositive proportion after the second dose of about 79% [6].…”

Section: Introductionmentioning

confidence: 99%

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

et al. 2022

View full text Add to dashboard Cite

We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.

show abstract

Humoral Immunity After mRNA SARS-CoV-2 Vaccination in Allogeneic HCT Recipients—Room for Improvement and Much to Learn

Cited by 8 publications

References 7 publications

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation

The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation

Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Contact Info

Product

Resources

About